Financials
April 17, 2018 / 6:07 PM / a year ago

BRIEF-DelMar Pharmaceuticals Presents Positive Updates on 2 Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM

1 Min Read

April 17 (Reuters) - DelMar Pharmaceuticals Inc:

* DELMAR PHARMACEUTICALS PRESENTS POSITIVE UPDATES ON TWO ONGOING CLINICAL TRIALS WITH VAL-083 FOR TREATMENT OF MGMT-UNMETHYLATED GBM

* DELMAR PHARMACEUTICALS - NO DOSE-LIMITING TOXICITIES HAVE BEEN REPORTED FOLLOWING TREATMENT WITH MULTIPLE CYCLES OF VAL-083 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below